Terril Brothers Inc. Boosts Holdings in Globus Medical, Inc. (NYSE:GMED)

Terril Brothers Inc. grew its stake in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 47.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,365 shares of the medical device company's stock after acquiring an additional 25,450 shares during the period. Globus Medical accounts for 1.5% of Terril Brothers Inc.'s holdings, making the stock its 23rd largest position. Terril Brothers Inc. owned about 0.06% of Globus Medical worth $4,229,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Globus Medical by 49.7% in the third quarter. Vanguard Group Inc. now owns 11,245,502 shares of the medical device company's stock valued at $558,339,000 after buying an additional 3,732,959 shares in the last quarter. Paradice Investment Management LLC acquired a new stake in shares of Globus Medical in the third quarter valued at approximately $55,053,000. Bank of New York Mellon Corp raised its position in shares of Globus Medical by 80.0% in the third quarter. Bank of New York Mellon Corp now owns 2,406,682 shares of the medical device company's stock valued at $119,492,000 after buying an additional 1,069,419 shares in the last quarter. Nuance Investments LLC raised its position in shares of Globus Medical by 36.8% in the third quarter. Nuance Investments LLC now owns 3,620,518 shares of the medical device company's stock valued at $179,759,000 after buying an additional 974,693 shares in the last quarter. Finally, Burgundy Asset Management Ltd. raised its position in shares of Globus Medical by 300.4% in the third quarter. Burgundy Asset Management Ltd. now owns 1,033,770 shares of the medical device company's stock valued at $51,327,000 after buying an additional 775,615 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GMED shares. BTIG Research upgraded shares of Globus Medical from a "neutral" rating to a "buy" rating and set a $60.00 price target for the company in a research report on Monday, March 18th. Truist Financial lifted their price objective on shares of Globus Medical from $58.00 to $60.00 and gave the company a "hold" rating in a research note on Wednesday, February 21st. Stifel Nicolaus lifted their price objective on shares of Globus Medical from $61.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, February 21st. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price objective on shares of Globus Medical in a research note on Thursday, January 11th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $66.33.

Globus Medical Price Performance

Shares of NYSE GMED traded up $0.18 during midday trading on Friday, reaching $50.55. 545,156 shares of the company were exchanged, compared to its average volume of 891,173. The stock's 50-day moving average price is $53.00 and its 200-day moving average price is $51.31. The stock has a market cap of $6.84 billion, a P/E ratio of 43.21, a PEG ratio of 1.49 and a beta of 1.08. Globus Medical, Inc. has a one year low of $43.38 and a one year high of $62.88. The company has a quick ratio of 2.72, a current ratio of 4.88 and a debt-to-equity ratio of 0.10.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Tuesday, February 20th. The medical device company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.01. The firm had revenue of $616.53 million for the quarter, compared to analysts' expectations of $608.21 million. Globus Medical had a net margin of 7.83% and a return on equity of 8.82%. The company's revenue was up 124.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. On average, sell-side analysts anticipate that Globus Medical, Inc. will post 2.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Globus Medical news, Director Leslie V. Norwalk sold 10,590 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $51.99, for a total transaction of $550,574.10. Following the sale, the director now owns 17,419 shares of the company's stock, valued at $905,613.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 24.30% of the company's stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.